BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
-1.98%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$4.46B
AUM Growth
+$4.46B
(-14%)
Cap. Flow
-$467M
Cap. Flow
% of AUM
-10.47%
Top 10 Holdings %
Top 10 Hldgs %
48.58%
Holding
170
New
10
Increased
26
Reduced
81
Closed
22
Top Buys
| 1 |
Akero Therapeutics
AKRO
|
$50.6M |
| 2 |
AbbVie
ABBV
|
$18.9M |
| 3 |
Stryker
SYK
|
$17.3M |
| 4 |
Beam Therapeutics
BEAM
|
$17.1M |
| 5 |
Baxter International
BAX
|
$15.6M |
Top Sells
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$204M |
| 2 |
Arvinas
ARVN
|
$45.8M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$36.1M |
| 4 |
VRNA
Verona Pharma
VRNA
|
$32.2M |
| 5 |
Tandem Diabetes Care
TNDM
|
$28.2M |
Sector Composition
| 1 | Healthcare | 99.87% |
| 2 | Technology | 0.01% |
| 3 | Communication Services | 0.01% |
| 4 | Consumer Discretionary | 0% |
| 5 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Phreesia
PHR
$1.88B
| $9.61M | 0.22% | 376,163 -29,530 | -7% | -$755K |
|
77
Sarepta Therapeutics
SRPT
$1.78B
| $9.52M | 0.21% | 149,113 -22,204 | -13% | -$1.42M |
|
78
Humana
HUM
$36.5B
| $7.49M | 0.17% | 28,298 -69 | -0.2% | -$18.3K |
|
79
Labcorp
LH
$23.1B
| $6.55M | 0.15% | 28,141 +27,925 | +12,928% | +$6.5M |
|
80
Gilead Sciences
GILD
$140B
| $6.17M | 0.14% | 55,022 +6,593 | +14% | +$739K |
|
81
Castle Biosciences
CSTL
$696M
| $6.03M | 0.14% | 301,103 -444,879 | -60% | -$8.91M |
|
82
Evolent Health
EVH
$1.12B
| $5.82M | 0.13% | 614,337 -499,321 | -45% | -$4.73M |
|
83
Glaukos
GKOS
$5.5B
| $5.5M | 0.12% | 55,926 -4,949 | -8% | -$487K |
|
|
WAY
84
Waystar Holding Corp
WAY
$6.6B
| $5.4M | 0.12% | 144,426 -13,472 | -9% | -$503K |
|
85
Altimmune
ALT
$338M
| $5.28M | 0.12% | 1,056,793 +111,347 | +12% | +$557K |
|
86
Centene
CNC
$14.3B
| $5.23M | 0.12% | 86,218 -238 | -0.3% | -$14.4K |
|
87
Bio-Rad Laboratories Class A
BIO
$8.06B
| $5.23M | 0.12% | 21,476 -12,075 | -36% | -$2.94M |
|
88
Astrana Health
ASTH
$1.48B
| $5.06M | 0.11% | 163,155 -42,084 | -21% | -$1.31M |
|
89
BrightSpring Health Services
BTSG
$4.2B
| $4.37M | 0.1% | 241,749 +67,597 | +39% | +$1.22M |
|
90
Black Diamond Therapeutics
BDTX
$157M
| $4.24M | 0.09% | 2,733,547 -5,784,292 | -68% | -$8.97M |
|
|
VRNA
91
Verona Pharma
VRNA
$9.16B
| $3.89M | 0.09% | 61,261 -507,694 | -89% | -$32.2M |
|
92
Structure Therapeutics
GPCR
$1.11B
| $3.84M | 0.09% | 221,715 -263,335 | -54% | -$4.56M |
|
|
KMTS
93
Kestra Medical Technologies, Ltd. Common Stock
KMTS
$829M
| $3.33M | 0.07% | +133,761 | New | +$3.33M |
|
94
SPDR S&P 500 ETF Trust
SPY
$658B
| $3.17M | 0.07% | 5,660 | – | – |
|
95
Legend Biotech
LEGN
$6.41B
| $3.09M | 0.07% | 91,191 -76,150 | -46% | -$2.58M |
|
96
Pfizer
PFE
$141B
| $3.06M | 0.07% | 120,746 -20,814 | -15% | -$527K |
|
97
AstraZeneca
AZN
$248B
| $2.94M | 0.07% | 40,000 +4,300 | +12% | +$316K |
|
98
Cardinal Health
CAH
$35.5B
| $2.86M | 0.06% | 20,776 -1,522 | -7% | -$210K |
|
99
Illumina
ILMN
$15.8B
| $2.19M | 0.05% | 27,624 -16,079 | -37% | -$1.28M |
|
100
CVS Health
CVS
$92.8B
| $2.15M | 0.05% | 31,755 +9,911 | +45% | +$671K |
|